An Expanded Safety Study of Dapivirine Gel 4759 in Africa

This study has been completed.
Information provided by (Responsible Party):
International Partnership for Microbicides, Inc. Identifier:
First received: June 8, 2009
Last updated: September 9, 2011
Last verified: September 2011

June 8, 2009
September 9, 2011
November 2009
January 2011   (final data collection date for primary outcome measure)
  • Gynaecological examinations, including pelvic/speculum examination and colposcopy, and laboratory STI testing. [ Time Frame: Week 0, 1, 2, 4, 6 & 10 ] [ Designated as safety issue: Yes ]
  • Safety laboratory tests [ Time Frame: enrollment & last day of gel use ] [ Designated as safety issue: Yes ]
  • Adverse event/serious adverse event reports [ Time Frame: throughout study ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00917891 on Archive Site
  • Questionnaires concerning acceptability and adherence to daily use of vaginal gel. [ Time Frame: Week 0, 2, 6 & 10 ] [ Designated as safety issue: No ]
  • Documentation of adherence to the DMA method including the Applicator Collection Checklist, focus groups and male interviews. [ Time Frame: throughout study ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
An Expanded Safety Study of Dapivirine Gel 4759 in Africa
A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4759, 0.05%, 2.5g, a Vaginal Microbicide, Conducted Using Daily Monitored Adherence in Healthy, HIV-Negative Women.

The purpose of this study is to determine whether dapivirine gel 4759 is safe for daily use by healthy women in Kenya, Malawi, Rwanda, South Africa and Tanzania.

To reduce the influence of adherence as a factor in the interpretation of efficacy results, IPM is considering using a DOT (Directly Observed Therapy) based method for vaginal microbicide gel delivery in a future Phase III study. IPM has denoted this DOT based method as Daily Monitored Adherence (DMA). IPM014A is a Phase I/II study designed: (1) to assess and compare the safety of a once daily application of Dapivirine Gel 4759, 0.05% 2.5g and a matching vehicle placebo gel; (2) to assess the acceptability of a once daily application of Dapivirine gel 4759, 0.05% 2.5g and a matching vehicle placebo gel; and (3) to assess the feasibility of utilizing the DMA method for a large-scale phase III efficacy study.

Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • HIV Infections
  • Acquired Immunodeficiency Syndrome
  • Drug: dapivirine

    dosage form: vaginal gel

    dosage: 1.25mg dapivirine/day

    frequency: once daily

    duration: 6 weeks

  • Drug: placebo

    dosage form: vaginal gel

    frequency: once daily

    duration: 6 weeks

  • Placebo Comparator: vehicle placebo gel
    Intervention: Drug: placebo
  • Experimental: dapivirine gel
    Intervention: Drug: dapivirine
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
September 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Women 18 to 40 years of age inclusive who can give written informed consent
  2. Available for all visits and consent to follow all procedures scheduled for the study
  3. Agree to daily application of gel and monitoring as per Daily Monitored Adherence (DMA) method
  4. Healthy and self-reported sexually active
  5. HIV-negative as determined by a HIV rapid test at time of enrollment
  6. On a stable form of contraception and willing to continue on this stable method of contraception, OR, Have undergone surgical sterilisation at least 3 months prior to enrollment
  7. In the absence of the use of exogenous hormone(s), have a self-reported regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses
  8. Upon pelvic/speculum examination and colposcopy at the time of enrollment, the cervix and vagina appear normal as determined by the investigator
  9. Asymptomatic for genital infections at the time of enrollment
  10. Willing to refrain from use of vaginal products or objects within 14 days prior to enrollment and for the duration of the study
  11. Willing to answer acceptability and adherence questionnaires throughout the study
  12. Willing to refrain from participation in any other research study for the duration of this study
  13. Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures

Exclusion Criteria:

  1. Currently pregnant or last pregnancy outcome within 3 months prior to enrolment
  2. Currently breast-feeding
  3. Participated in any other research study within 60 days prior to screening
  4. Previously participated in any HIV vaccine study
  5. Untreated urogenital infections (either symptomatic or asymptomatic) within 2 weeks prior to enrollment
  6. Presence of abnormal physical finding on the vulva, vaginal walls or cervix during pelvic/speculum examination and/or colposcopy
  7. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction
  8. Pap smear result at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation
  9. Any Grade 2, 3 or 4 baseline haematology, chemistry or urinalysis laboratory abnormality according to the DAIDS Table for Grading Adverse Experiences
  10. Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrollment
  11. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex
  12. Any serious acute, chronic or progressive disease
  13. Any condition(s) that, in the opinion of the investigator, might interfere with adherence to study requirements or evaluation of the study objectives
18 Years to 40 Years
Contact information is only displayed when the study is recruiting subjects
Kenya,   Malawi,   Rwanda,   South Africa,   Tanzania
IPM 014A
International Partnership for Microbicides, Inc.
International Partnership for Microbicides, Inc.
Not Provided
Study Director: Dr Annalene Nel IPM
International Partnership for Microbicides, Inc.
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP